Illumina Ventures

Illumina Ventures is an influential venture capital firm focused on advancing genomics and precision health. Established in partnership with Illumina, the firm targets early-stage companies driving innovation in life science tools, therapeutics, diagnostics, and personal wellness. Their notable investments include leading companies like 23andMe, Twist Bioscience, and Sherlock Biosciences. Illumina Ventures primarily operates within North America but maintains a global investment scope. The firm typically leads investment rounds, with a strong emphasis on startups harnessing cutting-edge technologies like AI, machine learning, and synthetic biology to improve human health. Recent investments highlight their commitment to transformative technologies, with companies such as Actym Therapeutics and Redshift Bio joining their portfolio. Key figures at Illumina Ventures include founding partner Nick Naclerio, who brings extensive experience from his tenure at Illumina Inc., and Malek Faham, promoted to Chief Scientist. The team is complemented by experts like Thomas Ybert of DNA Script, underscoring the firm's robust support for its portfolio companies.